^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TL-532

    i
    Other names: TL-532
    Associations

    News

    Trials
    Company:
    Tollys
    Drug class:
    TLR3 agonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Chemically Defined TLR3 Agonist with Anticancer Activity. (PubMed, Oncoimmunology)
    In addition, in immunodeficient mice lacking formylpeptide receptor-1 (FPR1), TL-532 was able to restore the response of orthotopic subcutaneous fibrosarcoma to immunogenic chemotherapy. Altogether, these findings may encourage further development of TL-532 as an immunotherapeutic anticancer agent.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TL-532
    over2years
    The specific TLR3-agonist TL-532 induces life-long anti-tumor autovaccination, cross-immunity against unrelated cancers and reverses resistance to immune checkpoint inhibitors (AACR 2022)
    We identified TL-532 as spearhead of a new rationally designed TLR3-agonist family. In monotherapy, it demonstrated substantial tolerance and promising anti-cancer and autovaccinal activity, which included unrelated cancers. TL-532 also demonstrated its remarkable ability to overcome ICI tumor-resistance, thus increasing the clinical landscape for ICI combination treatment.
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • IFNA1 (Interferon Alpha 1)
    |
    TL-532